Mergers & Acquisitions Advisory
Senior-led, independent advisory on buy-side acquisitions, sell-side processes, and fairness opinions — exclusively in private markets across all major sectors and geographies.
Buy-Side Advisory
Comprehensive support across target identification, strategic screening, valuation, due diligence coordination, negotiation, and transaction execution for acquiring clients.
Sell-Side Advisory
End-to-end mandate management for owners and boards pursuing a sale, divestiture, or carve-out, including process design, marketing, and negotiation.
Fairness Opinions
Independent financial opinions delivered to boards and special committees in connection with proposed transactions, mergers, and related-party transactions.
Typical Sell-Side M&A Process
Representative M&A Transactions
Exclusive financial advisor to a women's health pharmaceutical business on its divestiture to a strategic acquirer. Managed the full sell-side process from positioning through close.
Financial advisor to a specialty pharmaceutical company in a landmark $28 billion acquisition, one of the largest pharma transactions of the year. Provided strategic counsel across valuation, negotiation, and transaction execution.
Exclusive financial advisor to a radiosurgery company in its $277 million acquisition of a radiation therapy platform, expanding its oncology technology portfolio.
Financial advisor to a contract research organisation (CRO) on its sale to a strategic buyer. Supported the full divestiture process including buyer outreach, due diligence coordination, and definitive agreement.
Exclusive financial advisor to an acquirer in its $380 million buy-side mandate to acquire a developer of cystic fibrosis therapeutics, a high-priority rare disease asset.
Exclusive financial advisor to a specialty pharmaceutical company on its $150 million sale to a strategic acquirer. Conducted a competitive process resulting in a premium outcome for the seller.
Exclusive financial advisor to a home healthcare services provider on its $343 million sale, navigating a complex regulatory landscape and coordinating across multiple qualified strategic bidders.
Exclusive financial advisor to a specialty pharmaceutical company on its $637 million sale. Managed a broad process with institutional strategic buyers and coordinated regulatory clearance planning.
Exclusive financial advisor to an ophthalmic surgery products company on its $2.8 billion sale — a landmark transaction in the ophthalmic devices sector. Managed full process from pre-launch positioning to close.
Exclusive financial advisor to a cochlear implant manufacturer on its $489 million sale to a strategic acquirer, supporting a competitive process across global hearing technology buyers.
Exclusive financial advisor to an animal health company in the acquisition of veterinary products business units from a diversified life sciences group. Advised on strategic fit, structure, and transaction execution.
Discuss an M&A Mandate
Contact our investment banking team to discuss your transaction requirements in confidence.
The information presented on this page is intended for institutional counterparties and professional investors only. All references to target returns, yield strategies, and projected outcomes represent forward-looking estimates subject to material market, credit, liquidity, and operational risks. Past performance is not indicative of future results. Nothing herein constitutes an offer to buy or sell securities or investment products.